What are the NCCN guidelines for targeted therapies to treat acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

NCCN guidelines also recommend the following targeted therapies for patients who are not candidates for intensive remission induction therapy or who decline intensive therapy [25] :

  • IDH1-mutated AML - Ivosidenib
  • IDH2-mutated AML -  Enasidenib

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!